Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

Protox Therapeutics completes US$2.3 million private placement

Fasken
Reading Time 1 minute read Subscribe
Client

Protox Therapeutics Inc.

On May 20, 2009, Protox Therapeutics Inc. (TSX: PRX) announced that it had closed its previously announced private placement of common shares, resulting in gross proceeds to Protox of approximately $2.31 million. Canaccord Capital Corporation acted as placement agent for the announced $1.5 million private placement and exercised an over-allotment option to sell common shares of Protox for additional gross proceeds of approximately $0.81 million. Protox will use the net proceeds of the offering to finance its clinical activities. Protox is a leader in advancing novel, receptor targeted fusion proteins. Protox was advised on this transaction by Fasken Martineau with a team that included Iain Mant and Benjamin Lee, assisted by paralegal Chin Yen Lee.

    Subscribe

    Receive email updates from our team

    Subscribe